Equity
€114,212 from €797,019 in 2019
Equity fell by 86% in 6 years.
Center for sight - Dr. E. Mertens
Lifetime
11 annual accounts with figures on one time axispeak €2.6m (2015)
€1.8m▼ 23.5%
peak €1.3m (2024)
€752,616▼ 42.7%
peak €797,019 (2019)
€114,212▼ 35.3%
€1.3m▼ 33.1%
peak 10.3 FTE (2016)
9.2 FTE▲ 3.4%
Board3 names since 2014
3 directorsErik Mertens and 2 others
Owners
Documentsfilings and deeds
30-06-202631 days before the deadline
2025financial year
Gross margin from €2.4m to €1.8mResult from €1.3m to €752,6163 directors reappointed 25-08Dividend €365,000Equity from €176,596 to €114,212Debts from €1.9m to €1.3m
Key points
from the 2025 annual accountsResult
€752,616 ▼ 42.7%
The result fell in 2025 from €1.3m to €752,616.
Debts
€1.3m 92% of the balance sheet
Financial debts 1%Suppliers 18%Taxes and wages 6%Other 75%
Of this, €1.2m falls due within a year.
Staff
10 employees on 31-12-2025
In 2025, 12 people joined and 13 left.
Filings
11 annual accounts since 2015
Two of the last ten came late. The 2016 accounts came latest: 87 days after the end of the period.
Position in the sector
8.2%
Lower solvency than 86% of companies in human health. Sector median 57.8% · 784 companies.
Checked score
91
Excellent
Financially stronger than 30% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,183 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%lowest value
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.2%▲ +0.1 percentage points vs 06-2026
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.3%▲ +0.1 percentage points vs 08-2026highest value
10-2026: 0.1%▼ -0.2 percentage points vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Equity €114,212 (8.2% of total assets)
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 0.48, cash €445,271
Figures for financial year 2025 (filed on 30-06-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 13% of them on solvency, 13% on liquidity, 80% on profitability and 16% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 1,325 companies had the same profile as Center for sight - Dr. E. Mertens has now. Each dot stands for 4 companies, two years later.
95.2%
were still trading
3.2%
stopped another way
1.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Center for sight - Dr. E. Mertens itself is lower: 0.1% within 12 months. It rests on far more data about Center for sight - Dr. E. Mertens than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,325 companies, not a prediction for Center for sight - Dr. E. Mertens. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €10,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.48 (0.71 in 2024), below 1. Short-term debt is 82.7% and cash 31.9% of total assets. 91.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 784 sector peers (2025).
NBB · sector comparisonPosition among 784 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
31 days early
2024
30 days early
2023
33 days early
2022
36 days early
2021
33 days early
2020
11 days early
2019
21 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 28 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Amendment of the articles
Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0553942551
3 directors reappointed
Eqiris, Erik Mertens and Signifeye · Permanent representatives: Huib Lodewijks and Kathleen Moons · General meeting of 06-06-2025 · Gazette deed
1 director appointed
Permanent representatives: Huib Lodewijks and Kathleen Moons · Signifeye NV · General meeting of 19-12-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Center for sight - Dr. E. Mertens Antwerp | €1.4m | €1.8m | 8.2% | 9.2 |
| Dermatologie Kempenland Beerse | €1.9m | €1.0m | 1.3% | 10.8 |
| Drs. Lintermans - van Riet Antwerp | €1.2m | €1.0m | 25.6% | 10.2 |
| HAND 2 HAND Ghent | €1.4m | €1.1m | 33.6% | 7.7 |
| DERMPAT Ghent | €1.2m | €1.1m | 51.7% | 11.4 |
| Eqwal Stomacare Ghent | €2.7m | €1.4m | 45.5% | 7.6 |
| OPHTARA Brussels | €1.3m | €1.1m | 32.9% | 5.9 |
These companies have the same main activity as Center for sight - Dr. E. Mertens: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.2m and €2.7m, founded between 2006 and 2016.
Official details
Source: KBO- Status
- Active since 19-06-2014Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment unit
- 2.291.638.8562610 Antwerp, since 19-06-2014
- Financial year end
- 31 December
- Peppol
- Reachable since 15-12-2025
Annual accounts 2025
- ≈ €1.6mestimated
- €1.4m▼ 33.3%
- Employeeson 31-12-2025
- 10▼ 9.1%
- Filing
- Filed on 30-06-2026, 31 days before the end of the filing period
Insights on Center for sight - Dr. E. Mertens
Center for sight - Dr. E. Mertens has existed since 2014. The gross margin fell from €2.6m in 2015 to €1.2m in 2016, while staff rose from 7 to 10.3 full-time equivalents.
EQIRIS holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Center for sight - Dr. E. Mertens
- What is the company number of Center for sight - Dr. E. Mertens?
- The company number of Center for sight - Dr. E. Mertens is 0553.942.551. The VAT number is the same number with BE in front: BE 0553.942.551.
- Where is Center for sight - Dr. E. Mertens based?
- The registered office is at Boomsesteenweg 223, 2610 Antwerp.Company details
- What does Center for sight - Dr. E. Mertens do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Center for sight - Dr. E. Mertens?
- Center for sight - Dr. E. Mertens is a public limited company (NV).
- When was Center for sight - Dr. E. Mertens founded?
- Center for sight - Dr. E. Mertens was founded on 19-06-2014.
- Is Center for sight - Dr. E. Mertens still active?
- Yes, Center for sight - Dr. E. Mertens is an active enterprise in the KBO register.
- How many employees does Center for sight - Dr. E. Mertens have?
- Center for sight - Dr. E. Mertens had an average of 9.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Center for sight - Dr. E. Mertens fall under?
- In its 2025 annual accounts, Center for sight - Dr. E. Mertens states joint committee 330.04 (Health institutions and services).
- What is the turnover of Center for sight - Dr. E. Mertens?
- The turnover in financial year 2025 is ≈ €1.6m. This figure is estimated from the gross margin of €1.8m and 63 comparable companies (NACE 86). It probably lies between €1.5m and €2.3m. In financial year 2023 turnover was €6.1m.
- Is Center for sight - Dr. E. Mertens profitable?
- In financial year 2025, Center for sight - Dr. E. Mertens made a profit of €752,616.
- Where can I find the annual accounts of Center for sight - Dr. E. Mertens?
- Center for sight - Dr. E. Mertens filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Center for sight - Dr. E. Mertens due?
- Center for sight - Dr. E. Mertens must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies See the other companies in the same group.Signifeye · 12 companies
See how customers, suppliers and banks see your own company and what to improve first.